Conjugated Estrogens Monograph Withdrawal Would Be Premature - Duramed
Wyeth-Ayerst's efforts to have the U.S. Pharmacopoeia monographs on conjugated estrogens withdrawn "insinuat[es] that it will not fulfill its responsibility to conclusively identify the active ingredients in its product any time soon," Duramed alleges in an Aug. 4 response to a Wyeth petition.
You may also be interested in...
Modifications to a branded drug's U.S. Pharmacopeia monograph could pose impediments to generic entry, Frommer, Lawrence & Haug attorney Andrew Berdon said
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011